IP Library Granted Patent US 12,674,797
Granted Patent B2
US 12,674,797 · App. 17/762,210 · Granted Jul 7, 2026

Method for measuring nucleic acid content in lipid nanoparticles using ultraviolet spectrometry

Inventors: Lee J. Klein (Collegeville, PA); Leia C. Epstein (Norristown, PA)
Assignee: Merck Sharp & Dohme LLC
G01N33/52A61K9/1271G01N21/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,674,797
App. No.
17/762,210
Filed
Mar 21, 2022
Granted
Jul 7, 2026
Kind
B2
Art Unit
1758
USPC
436/94
Abstract

An ultraviolet (UV) absorbance assay for measuring the concentration of large RNA molecules such as mRNA in suspensions comprising RNA-lipid nanoparticles (RNA-LNPs) is described.

Claims (183)

1 . A method for measuring the ribonucleic acid (RNA) concentration of a suspension of RNA-lipid nanoparticle (RNA-LNPs) wherein the RNA-LNPs comprise ionizable cationic lipids and the RNA is at least 100 nucleotides in length, the method comprising:

(a) mixing a suspension of RNA-LNPs comprising ionizable cationic lipids and RNA at least 100 nucleotides in length with an assay diluent comprising (i) a surfactant that disrupts the RNA-LNPs into their RNA and LNP components and is optically transparent at λ max of the RNA and (ii) an alkylamine that denatures the RNA by providing a pH of at least pH 11 or about pH 12, displaces the ionizable cationic lipids of the LNP that are associated with or complexed to the denatured RNA, and is optically transparent at λ max of the RNA, to provide a diluted sample solution;

(b) measuring absorbance of the diluted sample solution at lambda maximum of the RNA (λ max ) to provide a Net Absorbance or measuring absorbance of the diluted sample solution at λ max and at 400 nm and subtracting the absorbance at 400 nm from the absorbance at λ max to provide an adjusted Net Absorbance; and

(c) using the Net Absorbance or the adjusted Net Absorbance to determine the RNA concentration in the suspension of the RNA-LNPs.

2 . The method of claim 1 , wherein the alkylamine comprises a tertiary amine of the formula NRR′R″ wherein R, R′, and R″ are each independently a C1 to C18 alkyl.

3 . The method of claim 1 , wherein the alkylamine is selected from the group consisting of N,N-dimethylbutylamine (DMBA; CAS 927-62-8), N,N-diethylethanamine (TEA; CAS 121-44-8), N,N-diisopropylethylamine (DIPEA; CAS 7087-68-5), and hexan-1-amine (1-HA; CAS 111-26-2).

4 . The method of claim 1 , wherein the surfactant is selected from the group consisting of sodium dodecyl sulfate (SDS; CAS 151-21-3), cetyltrimethylammonium bromide (C-TAB; CAS 57-09-0), and polyethylene glycol alkyl ether (BRIJ).

5 . The method of claim 1 , wherein the surfactant is sodium dodecyl sulfate (SDS) and the alkylamine is N,N-dimethylbutylamine (DMBA) or the surfactant is a polyethylene glycol alkyl ether and the alkylamine is hexan-1-amine (1-HA).

6 . The method of claim 1 , wherein the ionizable cationic lipids comprise a tertiary amine.

7 . The method of claim 6 , wherein the ionizable cationic lipid comprises a tertiary amine and at least one saturated or unsaturated hydrocarbon chain comprising at least nine carbon atoms.

8 . The method of claim 1 , wherein the ionizable cationic lipid is dilinoleylmethyl-4-dimethylaminobutyrate (D-Lin-MC3-DMA; CAS 1224606-06-7).

9 . The method of claim 1 , wherein the assay diluent further includes a metal chelator.

10 . The method of claim 1 , wherein the assay diluent comprises about 750 mM N,N-dimethylbutylamine, about 10% (w/v) SDS, and about 1 mM EDTA.

11 . The method of claim 1 , wherein the RNA concentration is determined using the formula

mRNA

(

mg

mL

)

=

(

Net

Absorbance

or

adjusted

Net

Absorbance

path

length

(

cm

)

)

×

(

40

μg

·

cm

mL

)

×

(

1

mg

mL

1000

μg

mL

)

×

Dilution

Factor

wherein

Dilution

Factor

=

Diluted

Sample

Solution

volume

(

μL

)

Initial

Sample

Suspension

volume

(

μL

)

.

12 . A method for measuring the ribonucleic acid (RNA) concentration of a suspension of RNA-lipid nanoparticle (RNA-LNPs), the method comprising:

(a) providing a predetermined volume of a sample suspension comprising RNA-LNPs wherein the RNA-LNPs comprise ionizable cationic lipids and the RNA is at least 100 nucleotides in length;

(b) mixing the sample suspension of RNA-LNPs with a predetermined volume of an assay diluent comprising (i) a surfactant that disrupts the RNA-LNPs into their RNA and LNP components and is optically transparent at λ max of the RNA and (ii) an alkylamine that denatures the RNA at a pH of at least pH 11 or about pH 12, displaces the ionizable cationic lipids of the LNP that are associated with or complexed to the denatured RNA, and is optically transparent at λ max of the RNA, to provide a diluted sample solution in which the RNA is denatured and dissociated from the ionizable cationic lipids;

(c) measuring absorbance of the diluted sample solution at lambda maximum of the RNA (λ max ) in the diluted sample solution to provide a Net Absorbance or measuring absorbance of the diluted sample solution at λ max and at 400 nm and subtracting the absorbance at 400 nm from the absorbance at λ max to provide an adjusted Net Absorbance; and

(d) using the Net Absorbance or the adjusted Net Absorbance and the formula

mRNA

(

mg

mL

)

=

(

Net

Absorbance

or

adjusted

Net

Absorbance

path

length

(

cm

)

)

×

(

40

μg

·

cm

mL

)

×

(

1

mg

mL

1000

μg

mL

)

×

Dilution

Factor

wherein

Dilution

Factor

=

Diluted

Sample

Solution

volume

(

μL

)

Initial

Sample

Suspension

volume

(

μL

)

 to determine the RNA concentration in the suspension of the RNA-LNPs.

13 . The method of claim 12 , wherein the alkylamine comprises a tertiary amine of the formula NRR′R″ wherein R, R′, and R″ are each independently a C1 to C18 alkyl.

14 . The method of claim 12 , wherein the surfactant is SDS and the alkylamine is N,N-dimethylbutylamine (DMBA) or the surfactant is a polyethylene glycol alkyl ether and the alkylamine is hexan-1-amine (1-HA).

15 . The method of claim 12 , wherein the ionizable cationic lipids comprise a tertiary amine.

16 . The method of claim 15 , wherein the ionizable cationic lipid comprises a tertiary amine and at least one saturated or unsaturated hydrocarbon chain comprising at least nine carbon atoms.

17 . The method of claim 12 , wherein the ionizable cationic lipid is dilinoleylmethyl-4-dimethylaminobutyrate (D-Lin-MC3-DMA; CAS 1224606-06-7).

18 . The method of claim 12 , wherein the assay diluent further includes a metal chelator.

19 . The method of claim 18 , wherein the metal chelator is ethylenediaminetetraacetic acid (EDTA).

20 . The method of claim 12 , wherein the assay diluent comprises about 750 mM N,N-dimethylbutylamine, about 10% (w/v) SDS, and about 1 mM EDTA.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2022
From: KLEIN, LEE J.; EPSTEIN, LEIA C.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 059327/0183 →
Continuity (2)
Provisional Application 62907103 · Sep 27, 2019
Related Publication 20220397570A1 · Dec 15, 2022
References Cited (18)
US 20120276209A1 · Cullis et al. · 2012 [cited by applicant]
US 20130245107A1 · de Fougerolles · 2013 [cited by examiner]
US 20130332084A1 · Boonefaes · 2013 [cited by examiner]
US 20170196809A1 · Bowman · 2017 [cited by examiner]
WO 2017070622A1 · 2017 [cited by applicant]
WO WO2018089540A1 · 2018 [cited by examiner]
WO 2018170260A1 · 2018 [cited by applicant]
IDT, Oligo quantification—getting it right, published Dec. 14, 2016, https://www.idtdna.com/pages/education/decoded/article/oligo-quantification-getting-it-right (Year: 2016). [cited by examiner]
Anastassia Kanavarioti, HPLC methods for purity evaluation of man-made single-stranded RNAs, Jan. 31, 2019, Scientific Reports, (2019) 9:1019 (Year: 2019). [cited by examiner]
Matsuzaki et al., Optical characterization of liposomes by right angle light scattering and turbidity measurement, Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1467, Issue 1, Jul. 31, 2000, pp. 219-226 (Year: … [cited by examiner]
Sylwia Studzińska and Bogusław Buszewski, Evaluation of ultrahigh-performance liquid chromatography columns for the analysis of unmodified and antisense oligonucleotides, Anal Bioanal Chem. Jun. 18, 2014;406(28):7127-71… [cited by examiner]
Li et al., Alkylamine ion-pairing reagents and the chromatographic separation of oligonucleotides, Dec. 14, 2018, Journal of Chromatography A, vol. 1580, Dec. 14, 2018, pp. 110-119 (Year: 2018). [cited by examiner]
Aranda IV, Roman et al., Comparison and evaluation of RNA quantification methods using viral, prokaryotic, and eukaryotic RNA over a 10(4) concentration range, Analytical Biochemistry, 2009, 122-127, 387. [cited by applicant]
Hashimoto, J.G. et al., Comparison of RiboGreen and 18S rRNA quantitation for normalizing real-time RT-PCR expression analysis, BioTechniques, 2004, 54-60, 36(1). [cited by applicant]
Integrated DNA Technologies. Oligo quantification—getting it right. Jan. 18, 2013 [online] [retrieved Jan. 19, 2021]. Available on the internet: URL: https ://www. idtdna.com/pages/education/decoded/article/oligo-quanti… [cited by applicant]
Jayaraman, Muthusamy et al., Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo, Angew. Chem. Int. Ed., 2012, 8529-8533, 51. [cited by applicant]
Sabnis, Staci et al., A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates, Molec. Thera., 2018, 1509-1519, 26. [cited by applicant]
Taoka, M. et al., An analytical platform for mass spectrometry-based identification and chemical analysis of RNA in ribonucleoprotein complexes, Nucleic Acids Research, 2009, 1-14, 37(21):e140. [cited by applicant]